Sutro Biopharma (STRO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

STRO Stock Forecast

Sutro Biopharma stock forecast is as follows: an average price target of $13.00 (represents a 614.29% upside from STRO’s last price of $1.82) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

STRO Price Target

The average price target for Sutro Biopharma (STRO) is $13.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $12.00. This represents a potential 614.29% upside from STRO's last price of $1.82.

STRO Analyst Ratings

Buy

According to 7 Wall Street analysts, Sutro Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for STRO stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Sutro Biopharma Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 11, 2024	Tazeen Ahmad	Bank of America Securities	$12.00	$3.60	232.87%	559.34%
Oct 11, 2024	Andrew Fein	H.C. Wainwright	$12.00	$3.61	232.41%	559.34%
Aug 16, 2024	Asthika Goonewardene	Truist Financial	$15.00	$4.21	256.29%	724.18%
May 14, 2024	James Shin	Deutsche Bank	$10.00	$4.34	130.41%	449.45%
May 14, 2024	David Nierengarten	Wedbush	$8.00	$4.23	89.13%	339.56%
Apr 03, 2024	Jay Olson	Oppenheimer	$10.00	$5.09	96.46%	449.45%
Apr 03, 2024	Edward Tenthoff	Piper Sandler	$11.00	$5.09	116.11%	504.40%
Apr 02, 2024	Asthika Goonewardene	Truist Financial	$18.00	$5.09	253.63%	889.01%
Jan 13, 2023		Truist Financial	$25.00	$8.13	207.31%	1273.63%
Jan 10, 2023		Piper Sandler	$18.00	$8.29	117.13%	889.01%
Jun 28, 2022	Edward Tenthoff	Piper Sandler	$16.00	$5.05	216.83%	779.12%

The latest Sutro Biopharma stock forecast, released on Oct 11, 2024 by Tazeen Ahmad from Bank of America Securities, set a price target of $12.00, which represents a 232.87% increase from the stock price at the time of the forecast ($3.60), and a 559.34% increase from STRO last price ($1.82).

Sutro Biopharma Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	8
Avg Price Target	-	$12.00	$12.00
Last Closing Price	$1.82	$1.82	$1.82
Upside/Downside	-100.00%	559.34%	559.34%

In the current month, the average price target of Sutro Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Sutro Biopharma's last price of $1.82. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 11, 2024	H.C. Wainwright	Underperform	Underperform	Hold
Oct 11, 2024	JMP Securities	Market Outperform	Market Outperform	Hold
Oct 11, 2024	Piper Sandler	Overweight	Overweight	Hold
Oct 11, 2024	Bank of America Securities	Buy	Buy	Hold
Oct 11, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 16, 2024	JMP Securities	Market Outperform	Market Outperform	Hold
Sep 16, 2024	H.C. Wainwright	Underperform	Underperform	Hold
Sep 16, 2024	Cowen & Co.	Buy	Buy	Hold
Aug 14, 2024	Cowen & Co.	Buy	Buy	Hold
Aug 14, 2024	Piper Sandler	Overweight	Overweight	Hold
May 14, 2024	Deutsche Bank	Buy	Buy	Hold
May 14, 2024	Wedbush	Outperform	Outperform	Hold
Apr 03, 2024	Oppenheimer	Outperform	Outperform	Hold
Apr 03, 2024	Piper Sandler	Overweight	Overweight	Hold
Mar 27, 2024	Oppenheimer	Underperform	Underperform	Hold
Mar 27, 2024	Wedbush	Buy	Buy	Hold
Mar 26, 2024	H.C. Wainwright	Buy	Buy	Hold
Jan 10, 2023	Piper Sandler	Overweight	Overweight	Hold
Jun 28, 2022	Piper Sandler	Overweight	Overweight	Hold

Sutro Biopharma's last stock rating was published by H.C. Wainwright on Oct 11, 2024. The company gave STRO a "Underperform" rating, the same as its previous rate.

Sutro Biopharma Financial Forecast

Sutro Biopharma Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$113.72M	$16.92M	$10.41M	$12.67M	$8.63M	$25.15M	$28.10M	$5.90M	$10.65M	$8.52M	$28.05M	$14.66M	$8.28M	$17.82M	$9.47M	$7.15M	$11.30M	$12.28M
Avg Forecast	$9.01M	$1.63M	$15.08M	$13.90M	$7.43M	$9.07M	$9.03M	$9.00M	$12.15M	$15.29M	$21.02M	$12.07M	$57.36M	$13.01M	$12.56M	$12.13M	$14.52M	$35.71M	$16.01M	$10.46M	$11.81M	$8.97M	$13.29M	$4.80M	$8.27M	$7.29M	$6.96M	$10.70M	$9.95M	$9.86M
High Forecast	$9.01M	$1.63M	$15.08M	$13.90M	$7.43M	$9.07M	$9.03M	$9.00M	$23.28M	$15.29M	$21.02M	$12.07M	$83.82M	$13.20M	$12.56M	$12.13M	$14.52M	$35.71M	$16.01M	$10.46M	$11.81M	$8.97M	$13.29M	$4.80M	$8.27M	$7.29M	$6.96M	$10.70M	$9.95M	$9.86M
Low Forecast	$9.01M	$1.63M	$15.08M	$13.90M	$7.43M	$9.07M	$9.03M	$9.00M	$2.05M	$15.29M	$21.02M	$12.07M	$28.30M	$12.81M	$12.56M	$12.13M	$14.52M	$35.71M	$16.01M	$10.46M	$11.81M	$8.97M	$13.29M	$4.80M	$8.27M	$7.29M	$6.96M	$10.70M	$9.95M	$9.86M
# Analysts	2	2	2	2	1	1	1	4	8	4	3	4	7	5	6	3	2	2	2	2	3	4	5	9	13	8	8	9	12	7
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.98%	1.30%	0.83%	1.04%	0.59%	0.70%	1.76%	0.56%	0.90%	0.95%	2.11%	3.05%	1.00%	2.45%	1.36%	0.67%	1.14%	1.25%

Sutro Biopharma's average Quarter revenue forecast for Mar 24 based on 4 analysts is $12.07M, with a low forecast of $12.07M, and a high forecast of $12.07M. STRO's average Quarter revenue forecast represents a -89.38% decrease compared to the company's last Quarter revenue of $113.72M (Dec 23).

Sutro Biopharma EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	8	4	3	4	7	5	6	3	2	2	2	2	3	4	5	9	13	8	8	9	12	7
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$44.88M	$-44.01M	$-46.18M	$-39.68M	$-45.57M	$-18.76M	$-17.79M	$-37.69M	$-36.81M	$-28.96M	$-4.18M	$-28.21M	$-60.62M	$20.42M	$33.89M	$-17.44M	$-13.57M	$-10.54M
Avg Forecast	$-7.20M	$-1.30M	$-12.06M	$-11.11M	$-5.94M	$-7.25M	$-7.22M	$-7.20M	$-9.72M	$-12.23M	$-16.81M	$-41.46M	$-45.86M	$-10.40M	$-10.04M	$-37.69M	$-32.28M	$-32.40M	$-14.52M	$-34.26M	$-10.72M	$-8.14M	$-12.06M	$-25.39M	$-7.50M	$-6.61M	$-6.32M	$-13.65M	$-9.03M	$-8.94M
High Forecast	$-7.20M	$-1.30M	$-12.06M	$-11.11M	$-5.94M	$-7.25M	$-7.22M	$-7.20M	$-1.64M	$-12.23M	$-16.81M	$-33.17M	$-22.63M	$-10.24M	$-10.04M	$-30.15M	$-25.82M	$-32.40M	$-14.52M	$-27.41M	$-10.72M	$-8.14M	$-12.06M	$-20.31M	$-7.50M	$-6.61M	$-6.32M	$-10.92M	$-9.03M	$-8.94M
Low Forecast	$-7.20M	$-1.30M	$-12.06M	$-11.11M	$-5.94M	$-7.25M	$-7.22M	$-7.20M	$-18.62M	$-12.23M	$-16.81M	$-49.75M	$-67.02M	$-10.55M	$-10.04M	$-45.23M	$-38.73M	$-32.40M	$-14.52M	$-41.12M	$-10.72M	$-8.14M	$-12.06M	$-30.47M	$-7.50M	$-6.61M	$-6.32M	$-16.38M	$-9.03M	$-8.94M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-0.98%	4.23%	4.60%	1.05%	1.41%	0.58%	1.22%	1.10%	3.43%	3.56%	0.35%	1.11%	8.08%	-3.09%	-5.37%	1.28%	1.50%	1.18%

4 analysts predict STRO's average Quarter EBITDA for Mar 24 to be $-41.46M, with a high of $-33.17M and a low of $-49.75M. This is -192.37% lower than Sutro Biopharma's previous annual EBITDA (Dec 23) of $44.88M.

Sutro Biopharma Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	8	4	3	4	7	5	6	3	2	2	2	2	3	4	5	9	13	8	8	9	12	7
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$31.07M	$-49.28M	$-38.52M	$-50.05M	$-37.09M	$-17.77M	$-26.01M	$-39.09M	$-38.13M	$-30.90M	$-6.15M	$-30.36M	$-59.54M	$17.14M	$29.87M	$-19.59M	$-14.79M	$-12.91M
Avg Forecast	$-49.77M	$-51.68M	$-51.17M	$-54.84M	$-72.41M	$-63.60M	$-67.82M	$-70.01M	$-68.13M	$-60.27M	$-64.95M	$-44.33M	$-22.26M	$-60.39M	$-60.10M	$-40.30M	$-33.43M	$-23.45M	$-52.33M	$-36.63M	$-61.66M	$-52.90M	$-33.62M	$-27.32M	$-46.30M	$-41.19M	$-52.29M	$-15.34M	$-56.38M	$-51.31M
High Forecast	$-49.77M	$-51.68M	$-51.17M	$-54.84M	$-72.41M	$-63.60M	$-67.82M	$-66.75M	$-53.87M	$-60.27M	$-64.95M	$-35.46M	$-17.10M	$-60.39M	$-60.10M	$-32.24M	$-26.74M	$-23.45M	$-52.33M	$-29.31M	$-61.66M	$-52.90M	$-33.62M	$-21.86M	$-46.30M	$-41.19M	$-52.29M	$-12.27M	$-56.38M	$-51.31M
Low Forecast	$-49.77M	$-51.68M	$-51.17M	$-54.84M	$-72.41M	$-63.60M	$-67.82M	$-74.89M	$-89.52M	$-60.27M	$-64.95M	$-53.19M	$-25.51M	$-60.39M	$-60.10M	$-48.36M	$-40.11M	$-23.45M	$-52.33M	$-43.96M	$-61.66M	$-52.90M	$-33.62M	$-32.79M	$-46.30M	$-41.19M	$-52.29M	$-18.40M	$-56.38M	$-51.31M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-1.40%	0.82%	0.64%	1.24%	1.11%	0.76%	0.50%	1.07%	0.62%	0.58%	0.18%	1.11%	1.29%	-0.42%	-0.57%	1.28%	0.26%	0.25%

Sutro Biopharma's average Quarter net income forecast for Mar 24 is $-44.33M, with a range of $-53.19M to $-35.46M. STRO's average Quarter net income forecast represents a -242.69% decrease compared to the company's last Quarter net income of $31.07M (Dec 23).

Sutro Biopharma SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	8	4	3	4	7	5	6	3	2	2	2	2	3	4	5	9	13	8	8	9	12	7
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$15.07M	$15.27M	$15.00M	$15.51M	$14.72M	$14.64M	$15.14M	$15.04M	$15.76M	$16.59M	$12.54M	$11.11M	$10.38M	$9.08M	$8.64M	$8.71M	$8.70M	$8.12M
Avg Forecast	$6.87M	$1.24M	$11.51M	$10.61M	$5.67M	$6.92M	$6.89M	$6.87M	$9.27M	$11.67M	$16.04M	$9.21M	$43.77M	$9.92M	$9.58M	$9.26M	$13.82M	$26.93M	$12.07M	$7.89M	$8.91M	$6.76M	$10.03M	$3.62M	$6.24M	$5.49M	$5.25M	$6.82M	$7.51M	$7.43M
High Forecast	$6.87M	$1.24M	$11.51M	$10.61M	$5.67M	$6.92M	$6.89M	$6.87M	$17.77M	$11.67M	$16.04M	$9.21M	$63.96M	$10.07M	$9.58M	$9.26M	$16.59M	$26.93M	$12.07M	$7.89M	$8.91M	$6.76M	$10.03M	$3.62M	$6.24M	$5.49M	$5.25M	$8.18M	$7.51M	$7.43M
Low Forecast	$6.87M	$1.24M	$11.51M	$10.61M	$5.67M	$6.92M	$6.89M	$6.87M	$1.56M	$11.67M	$16.04M	$9.21M	$21.59M	$9.78M	$9.58M	$9.26M	$11.06M	$26.93M	$12.07M	$7.89M	$8.91M	$6.76M	$10.03M	$3.62M	$6.24M	$5.49M	$5.25M	$5.46M	$7.51M	$7.43M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.34%	1.54%	1.57%	1.68%	1.06%	0.54%	1.25%	1.91%	1.77%	2.45%	1.25%	3.07%	1.66%	1.65%	1.65%	1.28%	1.16%	1.09%

Sutro Biopharma's average Quarter SG&A projection for Mar 24 is $9.21M, based on 4 Wall Street analysts, with a range of $9.21M to $9.21M. The forecast indicates a -38.88% fall compared to STRO last annual SG&A of $15.07M (Dec 23).

Sutro Biopharma EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	8	4	3	4	7	5	6	3	2	2	2	2	3	4	5	9	13	8	8	9	12	7
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$0.51	$-0.81	$-0.00	$-0.85	$-0.73	$-0.34	$-0.55	$-0.84	$-0.83	$-0.67	$-0.13	$-0.66	$-1.61	$0.46	$1.00	$-0.84	$-0.64	$-0.56
Avg Forecast	$-0.61	$-0.63	$-0.62	$-0.67	$-0.88	$-0.78	$-0.83	$-0.85	$-0.83	$-0.73	$-0.79	$-0.92	$-0.27	$-0.74	$-0.73	$-0.78	$-0.62	$-0.29	$-0.64	$-0.76	$-0.76	$-0.65	$-0.41	$-0.62	$-0.57	$-0.51	$-0.64	$-0.69	$-0.69	$-0.63
High Forecast	$-0.61	$-0.63	$-0.62	$-0.67	$-0.88	$-0.78	$-0.83	$-0.81	$-0.66	$-0.73	$-0.79	$-0.92	$-0.21	$-0.74	$-0.73	$-0.78	$-0.62	$-0.29	$-0.64	$-0.76	$-0.76	$-0.65	$-0.41	$-0.62	$-0.57	$-0.51	$-0.64	$-0.69	$-0.69	$-0.63
Low Forecast	$-0.61	$-0.63	$-0.62	$-0.67	$-0.88	$-0.78	$-0.83	$-0.91	$-1.09	$-0.73	$-0.79	$-0.92	$-0.31	$-0.74	$-0.73	$-0.78	$-0.62	$-0.29	$-0.64	$-0.76	$-0.76	$-0.65	$-0.41	$-0.62	$-0.57	$-0.51	$-0.64	$-0.69	$-0.69	$-0.63
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-1.88%	1.10%	0.00%	1.08%	1.18%	1.18%	0.85%	1.11%	1.09%	1.03%	0.31%	1.06%	2.83%	-0.91%	-1.55%	1.22%	0.92%	0.89%

According to 4 Wall Street analysts, Sutro Biopharma's projected average Quarter EPS for Mar 24 is $-0.92, with a low estimate of $-0.92 and a high estimate of $-0.92. This represents a -280.70% decrease compared to STRO previous annual EPS of $0.51 (Dec 23).

Sutro Biopharma Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HLVX	HilleVax	$1.90	$32.00	1584.21%	Hold
STRO	Sutro Biopharma	$2.09	$13.00	522.01%	Buy
KROS	Keros Therapeutics	$18.00	$102.00	466.67%	Buy
AVTE	Aerovate Therapeutics	$2.56	$13.00	407.81%	Hold
OPT	Opthea	$3.27	$14.00	328.13%	Buy
LRMR	Larimar Therapeutics	$4.32	$17.00	293.52%	Buy
ANAB	AnaptysBio	$15.99	$49.83	211.63%	Buy
MLYS	Mineralys Therapeutics	$12.35	$30.00	142.91%	Buy
SNDX	Syndax Pharmaceuticals	$13.63	$31.67	132.36%	Buy
IDYA	IDEAYA Biosciences	$26.33	$53.33	102.54%	Buy
MRUS	Merus	$44.90	$81.25	80.96%	Buy
PCVX	Vaxcyte	$89.86	$148.80	65.59%	Buy
REPL	Replimune Group	$11.72	$19.00	62.12%	Buy
MGTX	MeiraGTx	$6.40	$9.00	40.63%	Buy
CNTA	Centessa Pharmaceuticals	$17.60	$23.25	32.10%	Buy

STRO Forecast FAQ

Is Sutro Biopharma a good buy?

Yes, according to 7 Wall Street analysts, Sutro Biopharma (STRO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of STRO's total ratings.

What is STRO's price target?

Sutro Biopharma (STRO) average price target is $13 with a range of $12 to $15, implying a 614.29% from its last price of $1.82. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Sutro Biopharma stock go up soon?

According to Wall Street analysts' prediction for STRO stock, the company can go up by 614.29% (from the last price of $1.82 to the average price target of $13), up by 724.18% based on the highest stock price target, and up by 559.34% based on the lowest stock price target.

Can Sutro Biopharma stock reach $3?

STRO's average twelve months analyst stock price target of $13 supports the claim that Sutro Biopharma can reach $3 in the near future.

What are Sutro Biopharma's analysts' financial forecasts?

Sutro Biopharma's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $34.53M (high $34.53M, low $34.53M), average EBITDA is $-27.611M (high $-27.611M, low $-27.611M), average net income is $-274M (high $-271M, low $-279M), average SG&A $26.35M (high $26.35M, low $26.35M), and average EPS is $-3.338 (high $-3.298, low $-3.397). STRO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $39.61M (high $39.61M, low $39.61M), average EBITDA is $-31.673M (high $-31.673M, low $-31.673M), average net income is $-207M (high $-207M, low $-207M), average SG&A $30.23M (high $30.23M, low $30.23M), and average EPS is $-2.529 (high $-2.529, low $-2.529).

Did the STRO's actual financial results beat the analysts' financial forecasts?

Based on Sutro Biopharma's last annual report (Dec 2023), the company's revenue was $153.73M, beating the average analysts forecast of $95.05M by 61.74%. Apple's EBITDA was $-89.278M, missing the average prediction of $-104M by -14.15%. The company's net income was $-107M, missing the average estimation of $-183M by -41.65%. Apple's SG&A was $62.58M, missing the average forecast of $72.53M by -13.71%. Lastly, the company's EPS was $-0.0018, missing the average prediction of $-2.524 by -99.93%. In terms of the last quarterly report (Dec 2023), Sutro Biopharma's revenue was $113.72M, beating the average analysts' forecast of $57.36M by 98.27%. The company's EBITDA was $44.88M, missing the average prediction of $-45.86M by -197.87%. Sutro Biopharma's net income was $31.06M, missing the average estimation of $-22.255M by -239.59%. The company's SG&A was $15.07M, missing the average forecast of $43.77M by -65.56%. Lastly, the company's EPS was $0.51, missing the average prediction of $-0.271 by -288.01%